

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	STARPHARMA HOLDINGS LIMITED
ABN	20 078 532 180

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jacinth K Fairley
Date of last notice	6 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	8 December 2023
No. of securities held prior to change	3,252,386 Ordinary Shares (direct) 748,048 Ordinary Shares (indirect) Fairley Family Super Fund Pty Ltd 55,000 Ordinary Shares (indirect) Dr Ian Fraser 5,765,207 Performance Rights (SPLAK)
Class	Performance Rights
Number acquired	667,441
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	3,252,386 Ordinary Shares (direct) 748,048 Ordinary Shares (indirect) Fairley Family Super Fund Pty Ltd 55,000 Ordinary Shares (indirect) Dr Ian Fraser 6,432,648 Performance Rights (SPLAK)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issuance of 667,441 CEO Rights to CEO Dr Fairley under the SPL Performance Rights Plan, approved by Shareholders at the 2023 AGM (refer to Resolution 6). This offer of performance rights is for the performance period starting from July 2023 to January 2024, whilst Dr Fairley is employed as CEO and Managing Director at Starpharma. The vesting of the CEO Rights is subject to the achievement of performance conditions as well as Corporate KPIs set during the performance period.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.